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The tumor microenvironment restrains conventional T cell (Tconv)
activation while facilitating the expansion of Tregs. Here we
showed that Tregs’ advantage in the tumor milieu relies on sup-
plemental energetic routes involving lipid metabolism. In murine
models, tumor-infiltrating Tregs displayed intracellular lipid accu-
mulation, which was attributable to an increased rate of fatty acid
(FA) synthesis. Since the relative advantage in glucose uptake may
fuel FA synthesis in intratumoral Tregs, we demonstrated that
both glycolytic and oxidative metabolism contribute to Tregs’ ex-
pansion. We corroborated our data in human tumors showing that
Tregs displayed a gene signature oriented toward glycolysis and
lipid synthesis. Our data support a model in which signals from the
tumor microenvironment induce a circuitry of glycolysis, FA syn-
thesis, and oxidation that confers a preferential proliferative ad-
vantage to Tregs, whose targeting might represent a strategy for
cancer treatment.
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Regulatory T cells (hereafter, “Tregs”), i.e., Foxp3-expressingCD4 T lymphocytes, are widely recognized as crucial con-
trollers of immune responses, and the balance between Tregs and
effector T cells determines the success of immune surveillance over
cancer progression. Therefore, understanding the dynamics that
dictate the relative Treg advantage over conventional T cells
(Tconvs) is of utmost importance in the design of cancer im-
munotherapies (1). Both thymus-derived Treg (tTreg) and pe-
ripherally induced Treg (pTreg) subsets populate the tumor
microenvironment (TME) (2): While the differentiation of pTregs
as well as in vitro-induced Tregs (iTregs) is favored in conditions
of poor T cell proliferation, both pTregs and tTregs can proliferate
actively in response to adequate signals (3, 4) and independently
contribute to generate the Treg pool in tumor-bearing hosts (5).
The T cell switch between quiescence and activation relies on
a metabolic shift from oxidative to glycolytic pathways, re-
spectively ensuring long-term survival and fueling fast energy
supply, biosynthesis, and replication (6). Distinct cellular subsets
display different metabolic signatures. Many pieces of evidence
suggest that Tconvs require amplifying oxidative pathways, while
blunting glycolysis, to undergo the terminal/restrained activation
that ultimately favors their differentiation into iTregs/pTregs (7–
9). First, mouse iTregs have been shown to preferentially use
fatty acid oxidation (FAO) (7, 8, 10); however glycolysis is es-
sential for human iTreg development upon suboptimal stimula-
tion, since the “moonlighting” enzyme enolase-1 suppresses the
transcription of the exon 2-containing FOXP3-splicing variant
(FOXP3-E2, a crucial determinant of the regulatory function)
unless engaged in glycolysis (11).
The proliferation of preestablished Tregs may have completely
distinct metabolic requirements with respect to the conversion of
Tconvs into iTregs/pTregs. Ex vivo, highly proliferative human
Tregs show active mTOR and high levels of the glucose trans-
porter Glut1; both glycolytic and FAO pathways contribute to
their expansion in vitro (12–14), and mTOR drives a lipogenic
and cholesterogenic signature in Tregs which crucially sustains
their expansion in vivo (15). Overall, these data indicate that
Tregs may arrange both glycolytic and oxidative routes and,
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similar to memory CD8 T cells (16), may also perform fatty acid
synthesis (FAS). This may be especially true in contexts of lim-
ited nutrient availability such as the TME, where tumor cells
glucose-restrict effector T cells, thus blocking their glycolytic
shift and antitumor activity (17, 18).
Here we hypothesized that Tregs may overwhelm Tconvs in
the hostile tumor context because of their peculiar ability to
exploit supplemental metabolic routes and thus optimize nutri-
ent usage. We first documented in a mouse tumor model that
tumor-infiltrating Tregs preferentially capture and utilize glucose
not only to fuel glycolysis but also to synthesize and accumulate
fatty acids (FAs) and that Tregs relied on FAS and FAO to a
higher extent than Tconvs in vitro. Genes involved in glycolysis
and lipid biosynthesis are enriched in the signature of activated
Tregs sorted from human liver cancer. Thus, exploiting a com-
bination of different metabolic routes may be an immune escape
mechanism that confers a selective advantage to Tregs in the TME.
Results
Proliferating Tregs in the TME Accumulate Intracellular Lipids. In the
visceral adipose tissue (VAT), expanded Tregs accumulate in-
tracellular lipids under the cell-intrinsic control of the adipo-
genic factor peroxisome proliferator-activated receptor gamma
(PPARγ) (19). Therefore, we first checked whether lipid accu-
mulation also occurred in Treg expansion in another context, i.e.,
in the TME. To this aim, CD4+Foxp3+ Tregs were analyzed by
flow cytometry, in comparison with CD4+Foxp3− Tconvs, in cells
extracted from tumor beds or, as control, from spleens of
C57BL/6 wild-type mice bearing nodules of the s.c.-implanted
colon carcinoma cell line MCA38 (the gating strategy is shown
in SI Appendix, Fig. S1). Confirming previous studies in a variety
of mouse tumor models and in human cancers (1), Treg frequency
was significantly increased at the tumor site (Fig. 1A). Compared
with spleen cells and Tconvs, Tregs extracted from the tumor bed
(TUM-Tregs) were more proliferative, as pointed out by Ki67+
frequency (Fig. 1B), and expressed higher levels of the receptor
OX40 (Fig. 1C), which we previously demonstrated sustains Treg
fitness in mouse models of homeostatic proliferation and colitis
(20) and promotes the expansion of stable and suppressive Tregs
in human cancers (21, 22).
When we stained the cells with Bodipy, a cell membrane-
permeable fluorophore specific for neutral lipid stores, we could
detect a higher intracellular lipid content in Tregs than in Tconvs
from both spleen and tumor bed (Fig. 1 D and E and SI Ap-
pendix, Fig. S1B); however, this phenomenon especially affected
TUM-Tregs, as evidenced by a significantly increased ratio of
Bodipy levels between Tregs and Tconvs in the tumor bed
compared with the spleen (Fig. 1F). Similar results were
obtained in a distinct tumor model, i.e., the s.c.-injected mela-
noma B16F10 (SI Appendix, Fig. S2).
To ascertain whether the preferential lipid accumulation in
Tregs was an exclusive feature of tumor or was shared with other
conditions characterized by Treg expansion, we analyzed Treg
frequency and intracellular lipid content in two distinct models
of liver disease, namely theMdr2−/− mouse in which an early-age
inflammatory cholangitis progresses to cirrhosis and cancer (23)
and the hepatitis C virus (HCV)-transgenic (HCVTg) mouse
which spontaneously develops steatosis at advanced age with no
evidence of inflammation (24). In young (3-wk-old) Mdr2−/−
mice, hepatic Tregs displayed a higher frequency than in wild-
type mice, and this was again associated with greater intracellular
lipid content than in Tconvs (SI Appendix, Fig. S3 A–C). Con-
versely, hepatic Tregs were not expanded in aged (>10-mo-old)
HCVTg compared with wild-type mice, and no preferential lipid
accumulation was detected in Tregs (SI Appendix, Fig. S3 D–F).
Overall these data indicate that Tregs enlarge their intracellu-
lar lipid pool when their expansion is triggered by either
inflammation- or tumor-associated stimuli.
We have previously demonstrated that OX40 plays non-
redundant roles in Treg expansion in a variety of contexts, in-
cluding cancer (20, 21); therefore, we sought to test whether the
OX40 signal could induce lipid accumulation in proliferating
Tregs. To this aim, we injected an anti-OX40 agonist mAb, OX86,
in naive mice. In agreement with published data (25), OX40
triggering induced a huge increase in Treg frequency (Fig. 2A).
This expansion was likely due to the direct promotion of the
selective proliferation of Tregs at the expense of Tconvs, as
demonstrated by the increased percentage of Ki67+ Tregs but
not Ki67+ Tconvs (Fig. 2B) and also corroborated by the de-
creased OX40 staining ex vivo (with the same OX86 clone) of
Tregs but not Tconvs of αOX40-treated mice (Fig. 2C). Notably,
αOX40-induced Treg expansion was associated with greater
Bodipy staining of Tregs, which was even more pronounced in
Ki67+ Tregs (Fig. 2 D and E). These results strengthen the link
between Treg proliferation and FA accumulation and demon-
strate that OX40 engagement alone can trigger the selective
proliferation of lipid-laden Tregs.
FAS, Rather than FA Uptake, Shapes the TUM-Treg Lipid Pool and
Promotes Treg Proliferation. In the adipose tissue, lipid-laden
Tregs also display higher levels of the FA translocator CD36
(19); therefore, we tested whether differential uptake of exoge-
nous FAs might account for the higher lipid content in TUM-
Tregs. We found that CD36 was modestly up-regulated at the
tumor site in both Tregs and Tconvs but without any specific
enrichment in TUM-Tregs (Fig. 3 A–C). Then we measured the
Fig. 1. Expanded and activated tumor-infiltrating Tregs display high in-
tracellular lipid content. MCA38 cells (5 × 105) were injected s.c. into C57BL/6
mice, and flow cytometry analysis was performed on lymphocytes
extracted from spleen (SPL) and tumor (TUM) after 14 d. (A) Frequency of
CD25+Foxp3+ Tregs in gated CD4+ lymphocytes. (B and C) Frequency of cells
expressing Ki67 (B) and geometric mean fluorescent intensity (gMFI) of
OX40 in gated CD25+Foxp3+ Tregs (red bars) and CD25−Foxp3− Tconvs (blue
bars) (C) in spleens (empty bars) and tumors (filled bars) from tumor-bearing
mice. (D and E) Representative histograms (D) and gMFI analysis (E) of Bodipy
incorporation in gated CD25+Foxp3+ Tregs (red peaks and bars) and
CD25−Foxp3− Tconvs (blue peaks and bars) in spleen (empty peaks and bars)
and tumor (solid peaks and bars) from tumor-bearing mice. Peaks in gray
represent the fluorescence-minus-one (FMO) controls. (F) Ratio of Bodipy
gMFI between Tregs and Tconvs from spleen and tumor. Error bars show
mean ± SEM; each dot corresponds to a single mouse. Data shown are from
one representative of two independent experiments. *P < 0.05, **P < 0.01,
***P < 0.005 by paired Student t test between Tregs and Tconvs in the
same samples and by unpaired Student t test between populations of
different samples.



























absorption in vivo of a fluorescently labeled FA (Bodipy FL C16,
a palmitic acid molecule conjugated to the Bodipy fluorophore),
previously injected into tumor-bearing mice. Both Tregs and
Tconvs tended to acquire less FA in the tumor site than in the
spleen (despite the modest CD36 up-regulation) but without any
major difference between the two subsets (Fig. 3 D–F). These
results suggested a local defect in FA distribution and uptake
shared by Tregs and Tconvs and unrelated to their CD36 levels,
and excluded preferential FA scavenging by TUM-Tregs. Therefore
we investigated whether, instead, intracellular FA metabolic routes
were involved in lipid accumulation and Treg proliferation. First, in
Tregs and Tconvs from tumor-bearing mice, we evaluated the ex-
pression levels of three selected genes, Pparg, Acacb, and Cpt1a,
respectively required for FA storage, FAS, and FAO. To this aim,
we adopted PrimeFlow RNA assay, allowing the simultaneous de-
tection of transcripts and proteins by flow cytometry at single-cell
resolution. With this approach, we could detect that TUM-Tregs
expressed all three genes at significantly higher levels than TUM-
Tconvs (Fig. 3G). Of note, Pparg and Acacb expression tended to
cosegregate in all cell types and at higher levels in TUM-Tregs (Fig.
3H), suggesting a link between PPARγ expression and FAS pro-
gramming specifically in these cells.
Therefore, we tested whether 5-(tetradecycloxy)-2-furoic acid
(TOFA), an inhibitor of acetyl-CoA carboxylase, a key enzyme in
the FAS cascade, impacted Treg proliferation. First, we admin-
istered TOFA to tumor-bearing mice, performing repeated
intratumor injections starting when nodules were palpable. This
treatment significantly suppressed tumor growth; however, this
effect was unlikely to be due to immune-mediated events, as we
failed to detect any significant increase in CD8 T cell frequency
or IFNγ production in TOFA-treated compared with mock-
treated nodules (SI Appendix, Fig. S4 A and B). Rather, direct
TOFA toxicity against tumor cells might account for the anti-
tumor activity observed in vivo. Indeed, TOFA also reduced the
viability of the MCA38 cell line in a dose-dependent fashion in
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Fig. 2. OX40 triggering alone recapitulates Treg proliferation and FA ac-
cumulation in vivo. C57BL/6 naive mice were injected i.p. with 500 μg
of anti-OX40 agonist mAb (OX86) or PBS as a mock control. After 6 d,
flow cytometry analysis was performed in splenocytes. (A) Frequency of
CD25+Foxp3+ Tregs in gated CD4+ lymphocytes. (B–D) Frequency of cells
expressing Ki67 (B), gMFI analysis of OX40 (C ), and gMFI analysis of Bodipy
incorporation (D) in gated CD25+Foxp3+ Tregs (red bars) and CD25−Foxp3−
Tconvs (blue bars) in αOX40-treated (solid bars) and mock-treated (open
bars) mice. (E) Representative histograms showing Bodipy labeling in gated
Ki67+ or Ki67− Tregs or Tconvs; numbers indicate Bodipy gMFI; peaks in gray
represent the FMO controls. Error bars show mean ± SEM; each dot corre-
sponds to a single mouse; six to seven mice were included in each exper-
imental group. *P < 0.05, **P < 0.01, ***P < 0.005 by paired Student t test
between Tregs and Tconvs in the same samples and by unpaired Student



















Fig. 3. FAS, rather than FA uptake, shapes the lipid Treg pool and con-
tributes to Treg proliferation. Mice bearing tumors 8 × 8 mm in size received
an i.p. injection of the green fluorescent palmitate (Bodipy FL C16) 1 h be-
fore spleen and tumor collection. Then Bodipy FL C16 uptake and
CD36 expression were quantified by flow cytometry in CD25+Foxp3+ Tregs
and CD25−Foxp3− Tconvs. (A and B) Representative histograms (A) and fre-
quency of cells expressing CD36 (B) in gated Tregs (red peaks and bars) and
Tconvs (blue peaks and bars) in spleen (empty peaks and bars) and tumor
(solid peaks and bars). (C) Ratio of the frequency of CD36-expressing Tregs
and Tconvs in spleen and tumor. (D and E) Representative histograms (D)
and gMFI of Bodipy FL C16 acquisition (E) in gated Tregs (red peaks and
bars) and Tconvs (blue peaks and bars) in spleen (empty peaks and bars) and
tumor (solid peaks and bars). (F) Ratio between Bodipy FL C16 gMFI of Tregs
and Tconvs in spleen and tumor tissue. Peaks in gray represent the FMO
controls. (G and H) The expression level of Pparg, Acacb, and Cpt1a mRNA
was assessed by the PrimeFlow RNA assay in gated CD4+CD25+ Tregs and
CD4+CD25− Tconvs. (G) gMFI of each gene expression in Tregs (red bars) and
Tconvs (blue bars) in spleen (empty bars) and tumor (filled bars). (H) Represen-
tative overlay contour plots of Acacb- and Pparg-coexpressing cells in the in-
dicated samples. Each dot corresponds to a single mouse; data shown are from
one representative of four independent experiments, each including three to
seven mice per group. Error bars show mean ± SEM; *P < 0.05, **P < 0.01, by
paired Student t test between Tregs and Tconvs in the same sample and by
unpaired Student t test between populations of different samples.
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To assess the role of FAS directly on Tregs, we took advantage
of a model of Treg proliferation in vitro which recapitulated the
lipid accumulation occurring in TUM-Tregs in vivo. To this aim,
Tregs were enriched from the spleens of naive mice and poly-
clonally stimulated in vitro in the presence of IL-2. In this con-
text we could detect increased incorporation in Tregs of the
Bodipy lipophilic fluorophore in proportion to the IL-2 dosage
and to the extent of proliferation (Fig. 4A). Notably, Bodipy
levels were higher in proliferating than in resting cells, in-
dicating active lipid accumulation during Treg cell division
(Fig. 4B). In this setting, TOFA treatment significantly inhibited
the proliferation of Tregs in a dose-dependent fashion and
completely abolished FA accumulation selectively in proliferat-
ing cells, demonstrating a key role for FAS in both the expansion
and lipid pool generation of Tregs (Fig. 4C). Of note, unlike
tumor cells, TOFA exposure did not exert a direct cytotoxic ef-
fect on Tconvs or Tregs but rather increased their survival (SI
Appendix, Fig. S5).
To ascertain whether lipid accumulation and FAS reliance
were preferential features of Tregs, we purified Tregs and
Tconvs from spleens of naive mice, labeled them with a pro-
liferation tracer, and cocultured them in the presence of IL-2.
According to the literature (26), Tregs and Tconvs proliferate to
a similar extent in the presence of IL-2 (Fig. 4D). Here, in basal
conditions, we found that Tregs showed significantly higher
Bodipy content but the same proliferation levels (as suggested by
eFluor670 mean fluorescence intensity levels) as Tconvs, in-
dicating that Tregs in vitro were also more prone to accumulate
lipids during cell division. Notably, the addition of TOFA sig-
nificantly reduced proliferation and Bodipy staining in both
Tregs and Tconvs; however, Tregs were significantly more sen-
sitive to such inhibition (Fig. 4 D and E).
Finally, we sought to test whether, when adoptively transferred
in vivo, TOFA-treated Tregs were less able to suppress the im-
munity elicited by primary growing tumors against a secondary
challenge, i.e., “concomitant immunity” (27). To this aim, mice
bearing palpable tumors received a second injection of tumor
cells alone or tumor cells admixed with TOFA- or mock-
pretreated Tregs. The analysis of CD8 T cells infiltrating grow-
ing secondary tumors revealed a trend for decreased IFNγ and
TNFα production in mice receiving tumor cells plus Tregs
compared with mice receiving tumor cells alone. Notably, this
suppressive effect was rescued when TOFA-treated Tregs were
cotransferred with tumor cells (SI Appendix, Fig. S6). Together
with in vitro data, these results point to a key role of FAS in Treg
proliferation and possibly also in Tregs’ suppressive function
in vivo.
Glycolysis and FAO both Contribute to Tregs’ Advantage in Cancer.
Memory CD8 T cells were shown to synthesize FAs from glucose
(16); therefore we hypothesized that Tregs also might fuel FAS
through a greater absorption of glucose relative to effector
T cells, which instead are damaged by glucose deprivation in the
TME (17, 18). First, in Tregs and Tconvs from tumors and
spleens, we analyzed the expression of Glut1, a prominent glu-
cose transporter in CD4 T cell activation (28) that is also relevant
for Treg proliferation (12). We found that Glut1 was up-regulated
in both Tconvs and Tregs at the tumor site compared with the
spleen; however, such induction was significantly higher in Tregs,
resulting in an increased relative ratio of Glut1 expression in Tregs
versus Tconvs in tumors (Fig. 5 A–C). To track glucose uptake in
vivo directly, we injected the fluorescent glucose analog 2-NBDG
into tumor-bearing mice. In line with previous data (17, 18), Tconvs
showed a massive defect in glucose uptake in tumor compared with
spleen; conversely, Tregs displayed a relatively low glucose ab-
sorption in spleen that was maintained in tumor, resulting in a
significant rescue of the Treg/Tconv relative ratio of glucose uptake
at the tumor site (Fig. 5 D–F).
Then, we analyzed the expression of selected glycolysis-related
genes (Hk2, Gapdh, and Eno1) in Tregs and Tconvs through the
PrimeFlow RNA assay. All three genes were significantly more
represented in TUM-Tregs than in TUM-Tconvs (Fig. 5G). In-
terestingly, in both Tregs and Tconvs, Hk2 and Eno1 [the latter
being a master regulator of human Treg metabolism and de-
velopment (11)] were repressed in tumors compared with spleens,
in line with a general contraction of glycolysis in the tumor context;
however, their expression remained higher in Tregs in both com-
partments, pointing to a preferential preservation of glycolytic ac-
tivity in Tregs in the TME (Fig. 5G, Right).
The results described above delineate a scenario in which the
Treg advantage in tumor may be sustained by the concomitant
engagement of glucose and lipid metabolic routes. To address this
possibility, we performed a metabolomic analysis of Tregs and
Tconvs isolated from tumors or spleens; profoundly different pro-
files emerged from these T cell subsets (Fig. 6A). In more detail, we













Fig. 4. Inhibition of FAS blocks proliferation and lipid accumulation pref-
erentially in Tregs in vitro. (A–C) CD4+CD25+ Tregs, magnetically purified
from splenocytes of naive C57BL/6 mice, were labeled with eFluor670 and
polyclonally stimulated for 4 d and then were stained with Bodipy and analyzed
by flow cytometry. (A) Representative histograms of eFluor670 dilution (Left)
and Bodipy incorporation (Right) in Tregs cultured with different IL-2 con-
centrations. (B) Representative plot of the proliferating and resting Treg gat-
ing strategy (Left) and a representative histogram of Bodipy incorporation
within each gate (Right). (C) Mean fluorescence intensity (MFI) of eFluor670 in
gated Tregs (Upper) and gMFI of Bodipy incorporation in gated resting and
proliferating Tregs (Lower) cultured with different TOFA concentrations. (D and
E) Magnetically purified Tregs and Tconvs were cocultured at a 1:1 ratio with
feeder cells, anti-CD3, and IL-2, with or without TOFA (5 μg/mL). After 4 d, cells
were stained with Bodipy and Foxp3, and flow cytometry analysis was per-
formed in gated Tregs (Foxp3+, red) or Tconvs (Foxp3−, blue). (D) Representative
overlay of Tregs and Tconvs in the indicated conditions; numbers indicate MFI of
eFluor670 or gMFI of Bodipy. (E) Analysis of eFluor670 MFI or Bodipy gMFI
(gated on proliferating cells) of Tregs (red bars) or Tconvs (blue bars), either
mock-treated (empty bars) or TOFA-treated (filled bars). Each condition was
tested in triplicate; data shown are from one representative of two independent
experiments. Error bars showmean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.005 by
unpaired Student t test.



























with Tregs extracted from the spleen (SPL-Tregs): TUM-Tregs
displayed a preserved pentose phosphate pathway but higher gly-
colytic flux and higher consumption of acetyl-CoA and of the first
intermediates of the tricarboxylic acid (TCA) cycle (citrate and
α-ketoglutarate) (SI Appendix, Fig. S7A). Of note, this profile was
paralleled by increased NADH/NAD+ and NADPH/NADP+ ratios
and lower ATP/ADP ratios (SI Appendix, Fig. S7B), suggesting that
in TUM-Tregs improved glucose usage may fuel the TCA cycle,
whose intermediates are likely diverted to FA biosynthetic pathways
rather than being fully oxidized to generate ATP.
To functionally validate the peculiar TUM-Treg metabolic sig-
nature, we analyzed the bioenergetic profile of Tregs and Tconvs
isolated from spleen or tumor and cultured in vitro for 12 h through
Seahorse assays. Basal glycolysis, as measured by the extracellular
acidification rate (ECAR) in tumor compared with spleen, was
repressed in Tconvs, as expected (18), but was strikingly enhanced
in Tregs (Fig. 6B). The rate of basal oxidative phosphorylation
(OxPhos), as assessed by oxygen-consumption rate (OCR), was
again inhibited in Tconvs at the tumor site but was maintained in
Tregs (Fig. 6C). For all the metabolic indexes analyzed, Tregs
showed a relative advantage over Tconvs specifically at the tumor
site, as evidenced by higher Treg/Tconv ratios (Fig. 6 D and E).
These data demonstrated that tumor-associated Tregs engage
both glycolysis and OxPhos for their expansion. To assess whether
these metabolic routes are differentially required for Treg and
Tconv proliferation, we performed the Treg/Tconv coculture assay
described above in the presence of 2-deoxyglucose (2DG) or eto-
moxir (Etx), selective inhibitors of glycolysis or FAO, respectively.
In line with previous results with human Tregs (14), 2DG pro-
foundly restrained proliferation and lipid accumulation to a similar
extent in both Tconvs and Tregs, suggesting that both cell types
require glycolysis to support cell division and FAS. Conversely,
Fig. 5. Glucose uptake and usage occur preferentially in Tregs in tumors.
Mice bearing tumors 8 × 8 mm in size received an i.p. injection of the fluo-
rescent glucose analog 2-NBDG, and spleens and tumors were collected 15 min
after injection. 2-NBDG uptake and GLUT1 expression were quantified by flow
cytometry in CD25+Foxp3+ Tregs and CD25−Foxp3− Tconvs. (A and B) Repre-
sentative histograms (A) and frequency of cells expressing GLUT1 (B) in gated
Tregs (red peaks and bars) and Tconvs (blue peaks and bars) in spleen (empty
peaks and bars) and tumor (solid peaks and bars); gray peaks represent the
FMO controls. (C) Ratio between frequency of GLUT1-expressing Tregs and
Tconvs in spleen and tumor. (D and E) Representative histograms (D) and MFI
of 2-NBDG acquisition (E) in gated Tregs (red peaks and bars) and Tconvs (blue
peaks and bars) in spleen (empty peaks and bars) and tumor (solid peaks and
bars). (F) Ratio between 2-NBDG MFI of Tregs versus Tconvs at different sites.
(G) Expression levels of the glycolysis-related genes Hk2, Gapdh, and Eno1,
evaluated through the PrimeFlow RNA assay in gated CD4+CD25+ Tregs (red
bars) and CD4+CD25− Tconvs (blue bars) from spleen (empty bars) and tumor
(filled bars). Each dot corresponds to a single mouse; data shown are from one
representative of three independent experiments each including three to
seven mice. Error bars show mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.005,
by paired Student t test between Tregs and Tconvs in the same sample and by
unpaired Student t test between populations of different samples.





Fig. 6. TUM-Tregs display higher levels of both glycolytic and oxidative
metabolism. (A) CD4+CD25+ Tregs and CD4+CD25− Tconvs were magnetically
purified from pooled spleens and tumors of tumor-bearing mice, and
metabolomic profiling was performed directly ex vivo by LC-MS/MS. The
heatmap displays the levels of each metabolite (in femtograms per cell) in
the indicated samples (minimum/maximum related to each metabolite). G6P/
F6P, glucose 6P/fructose 6P; Ribu5P/Ribo5P/Xilu5P, Ribulose 5P/Ribose 5P/
Xilulose 5P; DHAP/GAP, dihydroxyacetone phosphate/glyceraldehyde phos-
phate. (B–E) CD4+CD25+ Tregs and CD4+CD25− Tconvs were magnetically
purified from pooled spleens and tumors of tumor-bearing mice, and
quantification of the ECAR (B) and OCR (C) was performed by Seahorse
analysis after a 12-h stimulation with anti-CD3/anti-CD28. (B) Basal glycolysis,
(C) basal OxPhos, and (D and E) respective Treg/Tconv ratios for each index,
in the indicated conditions. Data shown are from one representative of two
independent experiments. Data are expressed as mean ± SEM of three
measurements, each collected in two to eight replicates. **P < 0.01, ***P <
0.005, by unpaired Student t test. (F) Magnetically purified Tregs and Tconvs
were cocultured at a 1:1 ratio for 4 d with or without Etx (100 μM) or 2-DG
(1 mM), stained with Bodipy and Foxp3, and analyzed by flow cytometry.
Analysis of eFluor670 MFI or Bodipy gMFI (gated on proliferating cells) in
Tregs (red bars) or Tconvs (blue bars) is shown in the indicated conditions.
Data are shown as mean ± SEM; each condition was tested in triplicate; data
shown are from one representative of two independent experiments. *P <
0.05, **P < 0.01, ***P < 0.005, by unpaired Student t test.
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Etx slightly, although significantly, affected Treg, but not Tconv,
proliferation, and it promoted a further increase in Bodipy staining
only in Tregs, indicating that FAO consumed the intracellular lipid
pool and contributed to cell division specifically in Tregs (Fig. 6F).
In analogy with the above-described effect of TOFA, we could not
test whether Etx blocked Treg proliferation in tumors in vivo, due to
its direct toxicity against tumor cells that overshadowed any immune-
mediated effect (SI Appendix, Fig. S4 D–F). However, taken to-
gether, the greater sensitivity to FAO blockade in the coculture
assay in vitro and the higher relative rate of OxPhos from tumors
ex vivo highlight the reliance of Tregs on FA utilization and
suggest that Tregs may display a relative resistance to glucose
restriction in the TME due to their special ability to engage
multiple metabolic routes, such as glycolysis and FAS/FAO.
Glycolytic and Lipid Biosynthetic Pathways Are Active in Human
Tumor-Associated Tregs. Compared with mouse tumors, Tregs in-
filtrating human cancers display greater complexity and hetero-
geneity, which are not completely understood especially in their
immunometabolic aspects. Human cancer-infiltrating Tregs reveal
a peculiar gene signature characterized by specific chemokine
receptors, immune checkpoints, and costimulatory molecules such
as OX40 (29, 30). Based on our recent work demonstrating that
OX40-expressing Tregs were expanded in hepatic cirrhosis and
liver and colon cancers and that OX40 was connected with tumor-
associated Tregs’ high proliferation, stability, and suppression (21,
22), we explored the gene signature of OX40+ Tregs freshly
extracted from specimens of liver cirrhosis and tumor (CT) or
from the peripheral blood (PB) of patients with chronic HCV
infection and hepatocellular carcinoma (HCC), in comparison
with OX40− Tregs and the same subsets of Tconvs (Fig. 7A). We
selected 216 genes showing a greater than twofold increase se-
lectively in OX40+ CT-Tregs and performed a pathway enrich-
ment analysis. Notably, among the significantly enriched pathways,
we could reveal two metabolic routes, namely glycolysis (P =
0.00148) and activation of gene expression by SREBF (P =
0.0466) (Fig. 7B and SI Appendix, Tables S1 and S2). Glycolysis-
related genes included GAPDH, TPI1, ENO1, and PKM2; all are
involved in the glycolytic cascade, and PKM2, in particular, is in-
volved in substrate phosphorylation. The up-regulated genes be-
longing to the SREBF-related pathway were SCD1 and PMVK,
respectively involved in the synthesis of monounsaturated FAs and
in the mevalonate pathway for cholesterol biosynthesis. In con-
clusion, these data demonstrate that human Tregs shift between
different metabolic routes in specific tissue contexts.
Discussion
The TME poses metabolic hurdles, such as hypoxia and glucose
restriction, to the development of protective antitumor immu-
nity. Nevertheless, this context favors the accumulation of pro-
liferating and activated Tregs. Our study demonstrates that this
advantage may rely on Tregs’ capacity to compete for glucose
and perform FAS at higher rates than Tconvs.
Whether Tregs utilize glycolysis for their functions has been a
matter of controversy in recent years. While it has been shown
that murine iTregs (mostly polarized in the presence of TGFβ)
show low glycolytic rates and that glycolysis inhibition promotes
their differentiation (7–10), human iTregs (differentiated with
suboptimal stimulation) rely strictly on glycolysis for develop-
ment and function (11). Human Tregs are highly glycolytic when
freshly analyzed from human blood and strongly require both
FAO and glycolysis for their proliferation in vitro, while Tconvs
rely only on glycolysis (14). Our present data confirm the same
requirements in murine cells in vitro and demonstrate that Treg
expansion in vivo in the tumor context is sustained by a strong
increase in the glycolytic rate of Tregs compared with Tconvs.
Others have shown that Glut1 is higher in proliferating Tregs
from the spleens of naive mice and that Glut1 overexpression
increased both glycolytic and oxidative metabolism in Tregs and
provoked Treg expansion in the spleen. However, these Tregs
showed signs of reduced stability and suppressive function (12,
28). These results suggest that an artificial boost in glycolysis
may uncouple proliferation from suppressive function in Tregs.
However, increasing data indicate that these two events are
tightly interconnected, especially in tissue contexts where Tregs
are activated. Indeed, despite their refractoriness to conventional
stimulation in vitro, Tregs are a highly proliferative population in
vivo in both mice and humans, and many pieces of evidence
demonstrate that activated Tregs, displaying a higher pro-
liferation rate, retain or even increase their suppressive ability in
several contexts (31). A few examples are the spontaneous de-
velopment of lethal autoimmunity due to impaired expansion of
suppressive Tregs in mTORC1 deficiency (15), the impaired
ability of OX40-null Tregs to suppress colitis because of defective
competitive fitness (20), the ability of OX40/OX40L to induce
the proliferation of highly suppressive human Tregs (21), and the
lower proliferative potential of Tregs in multiple sclerosis pa-
tients with more severe disease (32). In cancer mouse models and
cancer patients, a huge amount of data demonstrates that highly
proliferative and highly suppressive Tregs accumulate in tumors
(2). Accordingly, our current results show higher frequency of
Ki67+ and OX40+ Tregs at the tumor site, in association with an
increased glycolytic rate, higher Glut1 expression, and improved
competition for glucose. Combined with the well-established
notion of the superior suppressive function of tumor-infiltrating
Tregs, our data contribute in delineating a picture in which a





Fig. 7. Human Treg proliferation ex vivo from diseased liver is associated
with glycolytic and FAS-related gene expression. OX40+/OX40− CD45RAlow
Tregs and Tconvs were extracted and sorted from the PB and CT of five
patients with chronic HCV infection, and gene expression analysis was per-
formed. (A) Sorting strategy. (B) The fold-change was calculated for each
gene over the respective control (OX40− PB Tconvs for all Tconv samples and
OX40− PB Tregs for all Treg samples), and 216 genes up-regulated more than
twofold only in Treg OX40+ CT were selected for pathway analysis (https://
reactome.org/). The heatmap displays the fold-change over control in the
genes accounting for two pathways of interest among those showing sta-
tistically significant enrichment (P < 0.05).



























suppressive function of Tregs in certain tissues and especially
in cancer.
Foxp3 expression alone is sufficient to shift the metabolic
program from glycolysis to oxidative phosphorylation and en-
ables Tregs to resist low-glucose, high-lactate exposure (12, 33).
Such a default program may help Tregs maintain their quiescent
state in adverse conditions. However, our results indicate the
presence of active Treg proliferation in the tumor context, pos-
sibly sustained by glycolysis, and associated with the expression
of OX40 as a marker of Treg activation. Furthermore, OX40
engagement directly promotes the selective proliferation of lipid-
laden Tregs in vivo. Overall, considering these results, we pro-
pose that, on the one hand, Foxp3 induces a default oxidative
program to maintain Treg survival in a quiescent state; on the
other, the signal elicited through OX40 and possibly other cos-
timulatory receptors and other members of the TNF receptor
superfamily may superimpose a glycolytic and anabolic boost
over the oxidative program, allowing Tregs to exit from quies-
cence, undergo active proliferation, and perform an efficient
suppressive function.
De novo synthesized intracellular lipids may be utilized not
only for metabolic but also for functional purposes. Lipids are a
preferential source of acetyl groups for histone acetylation and
epigenetic reprogramming (34), and short-chain FA uptake has
been shown to support colonic Treg homeostasis by regulating
histone acetylation (35, 36). The stability of Foxp3 itself is in-
creased by acetylation (37) and thus may be sensitive to the
supply of lipid-derived acetyl groups. Lipids are also necessary
for the palmitoylation of crucial signaling proteins, for building
cell membranes and shaping their lipid composition and fluidity,
and for the synthesis of pro- as well as antiinflammatory lipid
mediators. Our results suggest that TUM-Tregs may perform
FAS not only to fuel FAO but also for other purposes. Indeed,
the high neutral lipid content and the metabolite signature ob-
served in TUM-Tregs ex vivo indicates that FAS may prevail
over FA consumption. The glycolytic rate was boosted in TUM-
Tregs to a greater extent than oxidative indexes, and the coin-
duction of Pparg and Acacb was higher than the Cpt1a increase in
TUM-Tregs. Finally, in vitro, Treg proliferation was more sen-
sitive to the blockade of FAS than of FAO. Human OX40+
tumor-infiltrating Tregs displayed a gene signature oriented to
glycolysis and lipid biosynthesis. Overall, these data indicate that
lipid biosynthetic pathways may dominate in active Treg expan-
sion in cancer and also in inflammatory conditions. Accordingly,
impaired Treg homeostasis in mTORC1-deficient mice is asso-
ciated with defective lipid biosynthesis (15).
According to our gene-expression analysis in OX40+ Tregs
extracted from human tumor, an SREBP-driven program may
support lipid biosynthesis in these cells. While no comprehensive
data exist on the role of this family of transcription factors in
Treg homeostasis and suppressive function, their function has
been clearly elucidated in CD8 T cell activation: SREBP is es-
sential for T cell transition from quiescence to activation through
the active promotion of membrane synthesis (38). We speculate
that, likewise, a program of lipid biosynthesis addressed to the
construction of functional membranes might support the local
proliferation of OX40+ Tregs in the TME. Indeed, the two
SREBP-related genes up-regulated in tumor OX40+ Tregs,
SCD1 and PMVK, may contribute to the biosynthesis of those
lipids, namely monounsaturated FAs and especially cholesterol,
that more profoundly impact on membrane fluidity, lipid-raft
formation, and T cell receptor clustering and signaling, as re-
cently demonstrated in CD8 T cells (39).
We report here that OX40 triggering in naive mice prompts
the proliferation of lipid-laden Tregs. Therefore, the OX40/
OX40L signal, occurring in the HCC microenvironment (21, 40),
may directly sustain Treg lipogenic program. Indeed, OX40 li-
gation induces TRAF6 activation in CD4 T cells (41), and
TRAF6 is a crucial driver of lipid metabolism in memory T cell
development (42). Therefore, we suggest that the signal of OX40,
possibly together with other members of the TNF receptor
family, may sustain the transition of Tregs into the effector phase
through the promotion of lipid biosynthetic pathways.
Our data show that Tregs accumulate intracellular lipids not
only in cancer but also in the context of inflammation-driven
expansion (early cholangitis in Mdr2−/− mice) and not in hepatic
steatosis in the absence of inflammation (HCVTg mice at ad-
vanced age). Therefore, Treg lipid loading seems to occur as a
result of Treg-intrinsic pathways (such as OX40 signaling) and
irrespective of the lipid profile in the surrounding tissue. In-
triguingly, we also could find high expression of PPARγ in TUM-
Tregs. PPARγ is a nuclear factor that, in response to lipid li-
gands, controls a program of FA uptake, glucose uptake, and
lipogenesis in the adipose tissue and also regulates a variety of
other functions in other organs and in immune cells (43). In
VAT-Tregs, PPARγ was shown to drive CD36 expression and
FA incorporation; however, treatment of PPARγ transfectants
with a synthetic agonist induced not only the Cd36 gene but also
other genes involved in lipid metabolism, such as Scd1 and
Cpt1a, among others (19). Therefore, PPARγ may be active in
both VAT- and TUM-Tregs, driving a similar program of lipid
rearrangement that is specifically instrumental to Treg expan-
sion. Whether certain endogenous FAs generated by lipogenesis
may bind (at relatively low affinity) and activate PPARγ is still
controversial (44). It is reasonable to think that PPARγ may be
activated as a consequence of increased FAS in TUM-Tregs; in
line with this hypothesis, we found a preferential cosegregation
of Pparg and Acacb expression in TUM-Tregs.
At the systemic level, starvation leads to a transient Treg ex-
pansion through the mediation of the leptin/mTOR axis (13);
indeed, conditions of poor nutrient availability may shift the
balance from growth and defense to maintenance of homeostasis
and switch the immune status from inflammation to immune
regulation. We propose that the tumor setting might configure as
a context of nutrient starvation at the microenvironmental level,
fostering immune-regulatory events. Whether leptin deprivation
plays a role in the local tumor-associated immune dysfunction,
and especially in Treg expansion, remains to be investigated.
While the link between obesity, chronic inflammation, and can-
cer risk is well established, it is still unclear whether systemic/
regional nutrient availability, adiposity, or metabolic inflammation
affects immune regulation at the tumor site. However, we have
recently elucidated that OX40+ Tregs accumulate in the VAT of
obese human subjects unless affected by colorectal cancer, sug-
gesting that the adipose tissue of obese individuals may represent
a regional reservoir for Tregs to be recruited to the tumor site
(45). Our present results suggest that perturbations in nutrient
accessibility at the microenvironmental level may impact not only
tumor cell but also immune cell functions. For instance, therapies
targeting FAS, directly or indirectly, are under development for
cancer treatment (46); based on our data, this approach may off-
target Tregs, and especially activated tumor-associated Tregs, and
it thus may act as a double-edged sword against both tumor cell
proliferation and immune regulation.
Materials and Methods
Tumor Cell Lines. MCA38 colon adenocarcinoma and B16F10 metastatic
melanoma cell lines, kindly provided by M. P. Colombo (Fondazione Istituto
di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan),were
cultured in complete DMEMwith high glucose (Gibco) supplemented with 10%
FBS (Gibco), 2 mM L-glutamine (Sigma-Aldrich), penicillin/streptomycin, non-
essential amino acids, sodium pyruvate (EuroClone), 50 μM 2-mercaptoethanol
(Sigma-Aldrich), and 10 mMHepes (Aurogene) at 37 °C in a humidified 5% CO2
atmosphere. To obtain transplanted tumors, tumor cells were s.c. injected into
the right flank of C57BL/6NCrl wild-type male mice (Charles River Laboratories).
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Mouse Models. HCVTg mice of the FL-N/35 transgenic lineage, expressing the
HCV polyprotein under the albumin promoter (24) were kindly provided by
H. Lerat (Institut National de la Santé et de la Recherche Médicale, Unité
U955, Université Paris-Est, Créteil, France) and were backcrossed for more
than 10 generations to the C57BL/6NCrl background before analysis. HCVTg
and C57BL/6NCrl mice were bred and maintained under conventional con-
ditions at the animal facility of the Dipartimento di Scienze Anatomiche,
Istologiche, Medico legali e dell’Apparato locomotore (SAIMLAL), in Sapi-
enza Università di Roma, under protocols approved by the Italian Ministry of
Health (authorization no. 481/2015-PR). Mdr2−/− (FVB.129P2-Abcb4 tm1Bor/J)
mice were obtained from the Jackson Laboratory and were maintained
under pathogen-free conditions at the Pasteur Institute animal facility
(Paris). For all experiments, mice were killed by cervical dislocation. Tumor-
bearing C57BL/6NCrl mice were killed 2 wk after s.c. tumor cell trans-
plantation, and tumor volume (in cubic millimeters) was calculated using the
formula: (smaller diameter)2 × larger diameter. For OX40 stimulation in vivo,
C57BL/6 mice received an i.p. injection of 500 μg of anti-OX40 mAb (OX86;
BioXcell); after 6 d, flow cytometry analysis was performed on splenocytes.
In Vivo Uptake Assays. To test in vivo uptake of glucose and lipids, tumor-
bearing mice received a single i.p. injection of 50 μg Bodipy-conjugated
palmitate (Bodipy FL C16; Life Technologies) 1 h before analysis or a single
i.p. injection of 100 μg the fluorescent glucose analog 2-NBDG [2-(N-(7-
Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose; Life Technologies]
15 min before analysis.
TOFA and Etx Intratumor Treatments. To test TOFA or Etx antitumor activity in
vivo, tumor-bearing mice received repeated intratumor injections of 250 μg
TOFA (Sigma) or 200 μg Etx (Sigma) at days 5, 8, 11, and 13 after s.c. tumor
transplantation. As control, DMSO or water was administered, respectively;
mice were killed at day 14 for analysis.
All in vivo experiments were authorized by the Italian Ministry of Health
and were performed in accordance with the institutional animal care and use
committee (Organismo preposto al Benessere Animale, SAIMLAL De-
partment, Sapienza University of Rome) and the national law (Dlgs 26/2014).
Lymphocyte Extraction from Murine Tissues. Murine tumor samples were
mechanically dissociated using a gentleMACS Octo Dissociator according to
the manufacturer’s instructions (Miltenyi Biotec), and mononuclear cells
were enriched through a 40/80 Percoll (GE Healthcare) density gradient,
collecting cells at the interface between the 40% and 80% Percoll solutions.
The same protocol was applied for hepatic lymphocyte extraction. Spleno-
cytes were obtained by spleen mechanical dissociation on 70-μm filter fol-
lowed by incubation with ammonium-chloride-potassium (ACK) lysing
buffer (Gibco) for 4 min at 4 °C. Lymph nodes were mechanically dissociated
on a 70-μm filter. Cells were collected in complete RPMI-1640 Dutch-
modified medium containing 10% FBS (Gibco), 2 mM L-glutamine (Sigma-
Aldrich), penicillin/streptomycin, nonessential amino acids, sodium pyruvate
(EuroClone), and 50 μM 2-mercaptoethanol (Sigma-Aldrich).
Flow Cytometry and PrimeFlow RNA Assay. Bodipy (BODIPY 505/515, 4,4-
Difluoro-1,3,5,7-Tetramethyl-4-Bora-3a,4a-Diaza-s-Indacene; catalog number
D3921; Thermo Fisher Scientific) is a cell membrane-permeant fluorophore
specific for neutral lipid stores known to stain lipid droplets in CD8 T cells (16).
For Treg analysis, cells were incubated 15 min at 37 °C with Fixable Viability
Dye eFluor780 (eBioscience) plus Bodipy or Nile Red (Enzo Life Sciences) dyes
for neutral lipid staining. Then staining with the following antibodies for
surface antigens was performed for 20 min at 4 °C: CD4 BrilliantViolet605,
CD25 BrilliantViolet510, and CD134 (OX-40) BrilliantViolet421 (all from
BioLegend); CD36 APC (BD Biosciences); and Glut1 PE (Novus Biologicals).
Finally, intracellular staining with Foxp3 PE-eFluor610 and Ki67 PE-Cyanine7
(both from eBioscience) was performed for 30 min at RT after cell fixation
and permeabilization for 30 min at 4 °C, using the Foxp3/Transcription
Factor Staining Buffer Set according to the manufacturer’s instructions
(eBioscience). For CD8 analysis, cells were restimulated 4 h with Cell Stimu-
lation Cocktail plus Protein Transport Inhibitor (eBioscience), stained with
Viability Dye eFluor780, CD8a BrilliantViolet785 (BioLegend), and CD44
BrilliantViolet510 (BioLegend), fixed/permeabilized with Cytofix/Cytoperm
solution according to the manufacturer’s instructions (BD Biosciences), and
finally stained with IFNγ PE (eBioscience) and TNFα PECy7 (BioLegend).
The PrimeFlow RNA Assay (Affymetrix/eBioscience) was performed
according to the manufacturer’s instructions. After surface staining and
fixation/permeabilization, target probe hybridization was performed using
type 1 (AlexaFluor647-conjugated) probes for Pparg and Eno1 mRNAs, type
4 (AlexaFluor488-conjugated) probes for Cpt1a and Hk2 mRNAs, and type 6
(AlexaFluor750-conjugated) probes for Acacb and Gapdh mRNAs. Mouse
β-Actin (Actb), conjugated with each probe type, was used as a positive
control. Cells were incubated for 2 h with the target probes at 40 °C in a
thermal incubator for microtubes and then were incubated with the pre-
amplification reagent for 2 h and with the amplification reagent for an
additional 2 h at 40 °C. After signal amplification, cells were incubated with
label probes at 40 °C for 1 h and then were washed and resuspended in
staining buffer for acquisition.
Datawere acquired on an LSR Fortessa cell analyzer (BectonDickinson) and
were analyzed with FlowJo software (version 10.1r5; Tree Star Inc.).
In Vitro Proliferation Assays. CD4+CD25+ Tregs and CD4+CD25− Tconvs were
magnetically purified from splenocytes of wild-type C57BL/6 mice using the
CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec), labeled with
10 μM of the cell proliferation dye eFluor670 (eBioscience) by incubation for
15 min at 37 °C in complete RPMI Dutch-modified medium, and cultured or
cocultured at 1:1 ratios in the presence of equal numbers of irradiated
(3,500 rad) autologous splenocytes plus soluble anti-CD3 (1 μg/mL; eBioscience)
and IL-2 (100 IU/mL; Roche), with or without TOFA (Sigma), Etx (Sigma), or
2-DG (Sigma) at different concentrations. After 4 d of culture, analysis of
eFluor670 dilution and Bodipy incorporation was performed in gated Foxp3+
Tregs or Foxp3− Tconvs by flow cytometry.
Adoptive Treg Transfer and Suppression of Concomitant Immunity in Vivo.
CD4+CD25+ Tregs were magnetically purified from splenocytes of wild-
type C57BL/6 mice and were cultured for 40 h in complete RPMI medium
with coated anti-CD3 (1 μg/mL) plus IL-2 (100 IU/mL) in the presence of TOFA
(5 μg/mL) or DMSO as a control. Recipient mice first received a primary tumor
inoculum of 105 MCA38 cells s.c. in the right flank. After 10 d, when primary
tumors were palpable, mice received a challenge inoculum in the opposite
flank, containing 105 MCA38 cells, either alone or admixed at a 1:1 ratio
with Tregs prepared as described above. After further 13 d, flow cytometry
was performed in lymphocytes extracted from draining lymph nodes
and tumors.
Seahorse Analysis. OCR and ECAR real-time measurements were performed
using an XFe-96 Extracellular Flux Analyzer (Seahorse Bioscience) in basal
condition in XF medium and also in response to 5 μM oligomycin, 1.5 μM
carbonylcyanide-4- (trifluoromethoxy)-phenylhydrazone (FCCP), or 1 μM
of antimycin and rotenone (all from Sigma-Aldrich) for the OCR profile and
in response to 10 mM glucose, 5 μM oligomycin, and 100 mM 2-DG (all
from Sigma-Aldrich) for ECAR analysis. Basal OxPhos (before oligomycin
addition) and ATP-linked OxPhos (the difference between basal OCR and
oligomycin-induced OCR) were calculated from the OCR profile as indices of
mitochondrial respiratory function. Basal glycolysis (after the addition of
glucose), maximal glycolysis (after the addition of oligomycin), and glycolytic
capacity (the difference between oligomycin-induced ECAR and 2-DG–
induced ECAR) were calculated from the ECAR profile as indices of glycolytic
pathway activation.
Metabolomic Analysis. CD4+CD25+ Tregs and CD4+CD25− Tconvs were mag-
netically purified from pooled splenocytes and tumors of C57BL/6 mice (n =
15) using the CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec).
Pellets were then resuspended in 250 μL methanol/acetonitrile 1:1 contain-
ing [U-13C6]-Glucose 1 ng/μL (internal standard; 389374; Sigma Aldrich) and
lysed by TissueLyser (Qiagen) for 3 min at the highest frequency. Lysates
were spun at 20,000 × g for 5 min at 4 °C. Supernatants were then passed
through a regenerated cellulose filter, dried, and resuspended in 100 μL of
MeOH for subsequent analysis. Metabolomic data were obtained on an API-
4000 triple quadrupole mass spectrometer (AB Sciex) coupled with an HPLC
system (Agilent) and a CTC PAL HTS autosampler (PAL System). The identity of
all metabolites was confirmed using pure standards. Quantification of different
metabolites was performed with an LC-MS/MS method using a cyano-phase
LUNA column (50 mm × 4.6 mm × 5 μm; Phenomenex). Methanolic samples
were analyzed by a 5-min run in negative ion mode with 30 multiple reaction
monitoring (MRM) transitions. The mobile phase A was 5 mM ammonium ac-
etate (pH 7.00) in MeOH. The gradient was 100% A for all the analysis with a
flow rate of 500 μL/min. MultiQuant software (version 3.0.2; SCIEX) was used
for data analysis and peak review of chromatograms. Quantitative evaluation
of all metabolites was performed based on calibration curves with pure stan-
dards; then data were normalized on numbers of total purified cells.
XTT Cytotoxicity Assay. To assess the cytotoxic effects of TOFA and Etx on
tumor cells in vitro, MCA38 cells were seeded at a concentration of 5 × 103
cells per well into 200 μL of complete DMEM in a flat-bottomed 96-well plate



























in the presence of different concentrations of TOFA and Etx or DMSO and
water as respective controls. Conditions without cells and cell treatment
with 0.05% saponin (Sigma-Aldrich) were used as negative and positive
controls, respectively. After 24 h of culture, the analysis of cell viability was
performed with the XTT Cell Proliferation Assay Kit (Cayman Chemical),
and absorbance was measured with a Multiskan FC microplate reader
(Thermo Scientific).
Human Samples. PB from healthy volunteers was obtained from the buffy
coats of healthy blood donors, anonymously provided by the Immunohe-
matology and Transfusion Center of Policlinico Umberto I. PB and liver
specimenswere obtained from five patients with chronic hepatitis C, cirrhosis,
and HCC (four males and one female, age 53–80 y) undergoing surgery or
liver transplantation at Istituto Nazionale dei Tumori Regina Elena or Sapi-
enza Università di Roma-Policlinico Umberto I. Human studies were per-
formed in accordance with the ethical guidelines of the 1975 Declaration of
Helsinki and were approved by the Institutional Ethical Committee (Com-
itato etico dell’Azienda Policlinico Umberto I, Authorization: RIF.CE: 4259).
Informed consent was obtained from all patients.
Human Treg/Tconv Sorting and Gene-Expression Analysis. Liver fragments from
patients were perfused and grossly mashedwith HBSS (EuroClone) containing
0.5 mg/mL collagenase IV (Sigma-Aldrich) and 50 ng/mL DNase I (Worthington).
Samples were incubated for 10 min at 37 °C and then were mechanically dis-
aggregated into single-cell suspensions. Mononuclear cells from patient PB
were also enriched by Lympholyte (Cedarlane Laboratories) density gradient.
T cells were enriched from mononuclear cells using the Pan T cell Isolation kit II
(Miltenyi Biotec) and, after treatment with Fixable Viability Dye eFluor780
(eBioscience) and with FcBlock (eBioscience) for 15 min at 4 °C, were stained for
surface markers: dump channel (CD14 APCeFluor780, CD56 APCeFluor780, and
CD8 APCeFluor780, all from eBioscience); CD4 AlexaFluor488 (eBioscience);
OX40 PE (ACT35; BD); CD45RA PerCPCy5.5 (BioLegend); CD127 PECy7
(BioLegend); and CD25 APC (BioLegend). Then OX40+ and OX40− subsets
in gated CD45RAlow Tregs and Tconvs were sorted using a FACSAria II cell
sorter (Becton Dickinson).
Total RNA was isolated using the mirVana miRNA Isolation Kit (Ambion)
following the standard protocol. Briefly, the lysates were extracted once with
acid-phenol chloroform and further purified to yield total RNA. Extracted
RNA was quantified with the RiboGreen RNA Quantitation Kit (Molecular
Probes) on an Infinite F200 plate reader (Tecan Trading AG). All extracted
RNA samples were quality controlled for integrity with a 2100 Bioanalyzer
system (Agilent Technologies).
Gene expression of whole transcriptomes was performed according to the
standard protocol. Total RNA was isolated, quality controlled, and quantified
as described above. For each sample 100 ng of total RNA were reverse
transcribed according to the Illumina TotalPrep RNA Amplification kit
(Ambion), and biotinylated cRNA was generated by in vitro transcription.
Washing, staining, and hybridization were performed according to the
standard Illumina protocol: Briefly, 750 ng of cRNA of each sample in a final
volume of 15 μL were hybridized onto Illumina HumanHT-12 v4 Expression
BeadChip arrays. Hybridization and scanning were performed according to
the manufacturer’s indications on an Illumina iScan System, and data were
processed with BeadStudio v.3 (Illumina). Arrays were quantile normalized,
with no background subtraction, and average signals were calculated on
gene-level data for genes whose detection P value was lower than 0.001 in
at least one sample.
Statistical Analysis. Statistical analysis was performed using Prism software
(version 6.0; GraphPad). A two-tailed unpaired Student’s t test was used to
analyze in vitro data and to compare ex vivo data from Tregs and Tconvs in
different samples. The two-tailed paired Student’s t test was applied to
compare ex vivo data from Tregs and Tconvs in the same sample. Every in
vitro and ex vivo assay was performed in duplicate, triplicate, or quadru-
plicate when possible; for all experiments, the number of repetitions is in-
dicated in the figure legend. In all graphs, bars show means ± SEM. In all
tests, P < 0.05 was considered statistically significant.
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